Friday, 18 Oct 2019

You are here

Young Lupus Patients Have Higher Mortality Risk

A retrospective study examined mortality rates by comparing 2740 UK lupus patients  who were matched 1:4 with controls from the UK Clinical Practice Research Datalink between 1999 and 2012. (Citation source http://buff.ly/1nJWKIT)

Incident SLE (n=2740) resulted in death in 227 patients with a mortality rate of 15.84/1000 person-years (PYs). When compared to 10,922 matched controls with 553 deaths (mortality rate of 9.51/1000 PYs), there is a 67% higher mortality rate in lupus patients (RR 1.67; 95% CI, 1.43 - 1.94).

Males and females with SLE were 64-80% more likely to die than those without lupus. 

The relative risk for death was highest at younger ages for patients with SLE but nearly the same by age 80 years, as age-specific mortality increased over time for both groups. The most common causes of death in SLE were usually cardiovascular, followed by malignancy.

Although improved therapies have reduced mortality in many autoimmune disorders, further measures are warranted to reduce higher mortality rates younger, males and females with SLE.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.